Developers testing new therapies for lupus
Human Genome Sciences is one of several developers working on a new advance for lupus. This Wall Street Journal piece looks at the pipeline for lupus, which includes programs at Bristol-Myers Squibb, Genentech and Biogen Idec. There hasn't been a new therapy approved for lupus in 50 years, but these new drugs--which include Orencia and Rituxan--are being tested as treatments for the disease rather than just the symptoms.
- read the The Wall Street Journal article on lupus
Related Articles:
New warning issued on Rituxan for lupus. Report
HGS adds positive data in extended lupus trial. Report
Be the first to comment
More stories about Genentech Rituxan lupus Biogen Idec pipeline New Drugs Bristol-Myers Squibb Human Genome Sciences
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets